Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05143840
Title Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (ALERTCML)
Acronym ALERTCML
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Augusta University
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.